PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33909350-2	2021	Recently, more than 50 cases have been reported presenting a combination of thrombosis, thrombocytopenia and remarkably high levels of anti-PF4/polyanion antibodies post-AZD1222 vaccination.	azd1222	170-177	platelet factor 4	Homo sapiens	140-143
33909350-13	2021	CONCLUSIONS: We found low prevalence of both thrombocytopenia and antibodies to PF4/polyanion-complexes among Norwegian health care workers after vaccination with AZD1222.	azd1222	163-170	platelet factor 4	Homo sapiens	80-83
34189538-0	2021	T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.	azd1222	31-38	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	69-74
34750205-0	2021	Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka.	azd1222	41-48	sorcin	Homo sapiens	98-101
34323939-11	2021	It is characterized by thrombocytopenia and anti-PF4 antibodies binding to platelets in AZD1222-dependent manner.	azd1222	88-95	platelet factor 4	Homo sapiens	49-52
34189538-2	2021	We characterized CD4+ and CD8+ T-cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 280 unique vaccine recipients aged 18-85 years who enrolled in the phase 2/3 COV002 trial.	azd1222	59-66	CD4 molecule	Homo sapiens	17-20
34189538-2	2021	We characterized CD4+ and CD8+ T-cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 280 unique vaccine recipients aged 18-85 years who enrolled in the phase 2/3 COV002 trial.	azd1222	59-66	CD8a molecule	Homo sapiens	26-29
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	111-118	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	6-11
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	111-118	CD4 molecule	Homo sapiens	21-24
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	111-118	CD8a molecule	Homo sapiens	57-60
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	172-179	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	6-11
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	172-179	CD4 molecule	Homo sapiens	21-24
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	172-179	CD8a molecule	Homo sapiens	57-60
34189538-5	2021	Furthermore, AZD1222-specific Th1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups.	azd1222	13-20	CD8a molecule	Homo sapiens	38-41
34189538-6	2021	T-cell receptor (TCR) beta sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses.	azd1222	207-214	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	185-190
34189538-6	2021	T-cell receptor (TCR) beta sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses.	azd1222	207-214	CD4 molecule	Homo sapiens	223-226
34189538-6	2021	T-cell receptor (TCR) beta sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses.	azd1222	207-214	CD8a molecule	Homo sapiens	232-235
34189538-7	2021	Overall, AZD1222 vaccination induced a robust, polyfunctional Th1-dominated T-cell response, with broad CD4+ and CD8+ T-cell coverage across the SARS-CoV-2 spike protein.	azd1222	9-16	CD4 molecule	Homo sapiens	104-107
34189538-7	2021	Overall, AZD1222 vaccination induced a robust, polyfunctional Th1-dominated T-cell response, with broad CD4+ and CD8+ T-cell coverage across the SARS-CoV-2 spike protein.	azd1222	9-16	CD8a molecule	Homo sapiens	113-116
34189538-8	2021	One Sentence Summary: Polyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222.	azd1222	145-152	CD4 molecule	Homo sapiens	37-40
34189538-8	2021	One Sentence Summary: Polyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222.	azd1222	145-152	CD8a molecule	Homo sapiens	46-49
34189538-8	2021	One Sentence Summary: Polyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222.	azd1222	145-152	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	104-109
35562373-2	2022	Anti-platelet factor-4 (PF4) antibodies were observed in patients following presentation of TTS, however it is unclear if AZD1222 was responsible for inducing production of anti-PF4.	azd1222	122-129	platelet factor 4	Homo sapiens	178-181
35228013-5	2022	When AZD2816 is used as a booster dose in animals primed with a vaccine encoding the original spike protein (ChAdOx1 nCoV-19/ (AZD1222)), an increase in binding and neutralising antibodies against Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) is observed following each additional dose.	azd1222	127-134	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	94-99
35493482-0	2022	SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19).	azd1222	93-100	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	11-16
35214780-0	2022	Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2.	azd1222	121-128	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	18-23
35214780-6	2022	In contrast, the heterologous prime-boost regimen using AZD1222 and BNT162b2 yielded the highest anti-spike IgG levels, which were 3-4.5 times more than the levels resulting from homologous AZD1222 and BNT162b2 vaccination, respectively.	azd1222	56-63	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	102-107
35214780-6	2022	In contrast, the heterologous prime-boost regimen using AZD1222 and BNT162b2 yielded the highest anti-spike IgG levels, which were 3-4.5 times more than the levels resulting from homologous AZD1222 and BNT162b2 vaccination, respectively.	azd1222	190-197	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	102-107
35042529-5	2022	Both vaccines induced spike protein-specific effector T cells which were dominated by type 1 helper T cell responses following AZD1222 vaccination.	azd1222	127-134	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	22-27